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Abstract
Chimeric antigen receptor (CAR) T-cells targeting CD19 have drastically improved the outcomes of B-cell malignancies; however, the success has not yet extended to myeloid malignancies such as acute myeloid leukemia (AML).
Main impediments in the development of CAR T therapy in AML include difﬁculty in identifying appropriate target
antigens that are speciﬁc to myeloid leukemia stem cells while sparing the healthy hematopoietic stem progenitor cells
(HSPCs). Herein, we discuss the current state of CAR T-cell therapy in AML, highlighting recent progress and limitations in clinical translation. We also discuss novel approaches in CAR T therapy development and potential strategies to
enhance anti-leukemic activity while minimizing toxicity to heathy cells to make CAR T-cell therapy a viable option for
patients with AML.
Keywords: CAR T for AML, Refractory AML, AML, Acute Myeloid Leukemia

1. Introduction

A

cute myeloid leukemia (AML) is characterized by the clonal expansion of immature
hematopoietic stem progenitor cells (HSPCs) in the
bone marrow that disrupts the maturation and
function of normal cells. Patients with AML generally experience an aggressive disease course with
high mortality, with allogeneic hematopoietic-cell
transplantation (HCT) being the only cure for most
patients [1]. Recent advances in donor availability
coupled with improvements in HCT modalities
have allowed an increasing number of patients with
AML to undergo transplant, and more than 3000
patients have received HCT in 2019 in the United
States, as reported to the Center for International
Blood and Marrow Transplant Research (CIBMTR),
up from a 1000 patients in 2000 [2]. Although HCT
has remained an important treatment option, it is
associated with severe side effects such as graft-

versus-host disease (GVHD) and slow immune
reconstitution. Additionally, relapse after HCT
occurs in approximately 25e50% of patients with a
two-year survival rate of <20% [3]. Additional safe
and efﬁcacious therapeutic options are greatly
needed to improve the clinical outcomes of patients
with AML.
Cancer immunotherapy has made signiﬁcant
strides in the treatment of hematologic malignancies
(HM) in recent years. Adoptive T-cell therapy using
CAR T-cells targeting CD19 have demonstrated
remarkable success in the treatment of B-cell acute
lymphoblastic leukemia (B-ALL) and other B-cell
malignancies. The ﬁrst-in-class anti-CD19 CAR
T-cell product tisagenlecleucel (tisa-cel) was used in
a phase II trial in 75 pediatric and young adult
relapsed or refractory B-ALL patients, with 81% of
patients achieving a complete remission (CR) at
three months and 50% achieving event-free survival
(EFS) at 12 months [4]. Another anti-CD19 CAR
T-cell product, axicabtagene ciloleucel (axi-cel), was
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compared to chemoimmunotherapy followed by
autologous stem-cell transplant in an international
phase III trial in patients with large B-cell lymphoma
refractory to or relapsed after ﬁrst-line therapy; at a
median follow up of 25 months, the overall response
rate (ORR) was 83% in the axi-cel group and 50% in
the chemoimmunotherapy group, with a 24-month
EFS of 41% and 16%, respectively [5].
The successes of CAR T therapy in the treatment
of B-cell malignancies have not yet translated to
AML, largely due to the lack of a suitable antigen
target exclusively expressed on myeloid leukemic
blasts. Additionally, while B-cell ablating therapy
is clinically tolerated and can be easily corrected
via intravenous immunoglobulin infusion, depletion
of myeloid cells leads to profound immunosuppression and high infection risk. Thus, creative solutions to overcome these barriers are urgently
required to develop effective AML CAR T-cell
therapy.

2. The current state-of-the-art CAR T therapy
in AML
Currently, there are 20 clinical trials evaluating
the use of CAR T therapy in AML, with only six
trials in the US (Table 1). All trials are in early
phases of clinical development. The most common
targets for CAR T therapy in AML are CD123, CD33,
and CLL1. CD123 and CD33 are present on AML
leukemic blasts, although they are also expressed on
healthy HSPCs.
2.1. Interleukin-3 receptor/CD123
Interleukin-3 receptor subunit alpha (IL-3RA or
CD123), is expressed on leukemic blasts in about
80% of AML patients as well as in normal HSPCs
and their progeny [6]. Aberrant CD123 expression
has been shown to be a reliable marker for monitoring minimal residual disease (MRD) [7] and
correlates with poor OS as well as failure to achieve
a CR after induction chemotherapy [8]. Conventional CAR T-cells targeting CD123 can lead to
durable remissions albeit at the cost of bone marrow
aplasia and profound myelosuppression. Thus,
patients are generally required to undergo subsequent HCT and must have a stem cell source available to become eligible for clinical trials. In 2015, a
phase I clinical trial using a lentivirus-transduced
second-generation CAR (autologous or allogeneic
CD123CAR-CD28-CD3z-EGFRt-expressing T lymphocytes) was initiated at the City of Hope in six
CD123þ AML patients, all of whom had relapsed
after HCT (clinicaltrials.gov identiﬁer: NCT02159495).

Patients received lymphodepleting therapy consisting of cyclophosphamide and ﬂudarabine followed
by CAR T-cell infusion. Although ﬁnal results have
not been published, preliminary results suggested
that two of those patients had achieved a CR with
bridge to second HCT, one patient continued to
remain in MRD-negative remission with good
engraftment and 100% donor chimerism at 5.4
months post infusion [9]. Two additional patients
had blast reduction. All toxicities were manageable
and there were no dose-limiting toxicities.
In an attempt to avoid complete myeloablation
and mitigate other side effects, researchers at the
University of Pennsylvania developed sequential
infusions of “biodegradable T cells” that were
incorporated with anti-CD123 CAR to diminish
CAR T-cell persistence in vivo and reduce the
risk of myeloablation (clinicaltrials.gov identiﬁer:
NCT02623582). Five patients with relapsed AML
received the RNA CART123 product. Unfortunately, although there was a biological effect as
manifested by fever and cytokine release syndrome
(CRS) in all patients, CD123þ leukemic blasts
persisted in the bone marrow and all patients had
disease progression within one month post CAR
T-cell infusion [10]. Additional efforts employing
lentivirus-transduced CART123 followed by CAR
T-cell depletion with alemtuzumab and a rescue
HCT are currently underway.
2.2. Myeloid lineage cell surface antigen CD33
CD33 is highly expressed on myeloid lineage
including myeloid progenitors and mature myeloid
cells [11]. Gemtuzumab ozogamicin is an anti CD33
indicated for the treatment of AML. A CD33-CAR T
construct using CD28 costimulatory domain was found
to exert potent inhibition of leukemia proliferation in
AML cell line in patient-derived xenograft models [12].
Based on results of this study, a clinical grade lentivirus-transduced CD33-redirected CAR T-cells therapy is currently ongoing in a phase I/II clinical trial for
children and young adults with relapsed/refractory (R/
R) AML at multiple locations across the United States
(clinicaltrials.gov identiﬁer: NCT03971799). It is expected
that treatment will induce profound myeloablation
such that a rescue HCT will be necessary to restore
normal hematopoiesis.
2.3. C-type lectin-like molecule-1/CLL1
C-type lectin-like molecule-1, also known as
CLL1, is an ideal candidate for AML CAR T-cell
therapy as it is highly expressed on leukemic stem
cells while being absent on granulocyte-

Table 1. Current clinical trials of chimeric antigen receptor (CAR) T-cell therapies.
Trial number (status)

Disease subtype (age)

Location

Strategies to mitigate toxicity

Anti-CD123

NCT04678336 (Recruiting)

R/R AML (1e29)

Children's Hospital of Philadelphia, PA, USA

NCT02159495 (Recruiting)

R/R AML (  12)
R/R BPDCN (  12)

City of Hope Medical Center,
California, USA

NCT03190278 (Recruiting)

R/R AML (18e65)

Multiple locations in the USA

NCT03766126 (Active, not
recruiting)

R/R AML (  18)

University of Pennsylvania, PA,
USA

NCT04230265 (Recruiting)

R/R AML (  18)

NCT04014881 (Recruiting)
NCT03556982 (Unknown)

R/R AML (18e70)
R/R AML (14e75)

NCT03114670 (Unknown)

AML relapsed after allo-SCT
(  18)

NCT03796390 (Unknown)

R/R AML (2e65)

Anti-CD123/CLL1

NCT03631576 (Unknown)

R/R AML (<70)

Anti-CD33

NCT03971799 (Recruiting)

R/R AML (1e35)

Universit€atsklinikum Carl Gustav Carus Dresden, Sachsen,
Germany (multiple locations)
Wuhan Union Hospital, China
The Afﬁliated Hospital of the
Chinese Academy of Military
Medical Sciences, Beijing, China
Afﬁliated Hospital to Academy of
Military Medical Sciences, Beijing, China
Hebei Senlang Biotechnology
Inc., Ltd., Hebei, China
Fujian Medical University,
Fujian, China
Multiple locations in the USA

Patients with marrow aplasia at
D28 ± 5 undergo allo-SCT; patients must have a stem cell
donor available
Using truncated EGFR in CAR
construct to eliminate persistence of CAR T-cells; patients
must have a stem cell source
available
T-cell receptor knockout to
reduce risk of GVHD; patients
must have a stem cell source
available
Fractionated dosing; patients
with marrow aplasia at D28 ± 5
undergo allo-SCT; must have a
stem cell donor available
Combination of a universal CAR
T-cell with a recombinant antibody derivative (TM123)
Escalated dosing
Not stated

NCT01864902 (Unknown)

R/R AML (5e90)

NCT02799680 (Unknown)

R/R AML (>50)

NCT04789408 (Recruiting)

R/R or secondary AML (  18)

NCT04884984 (Recruiting)

R/R AML (6e65)

NCT04923919 (Recruiting)

R/R AML (2e75)

Anti-CLL1

Chinese PLA General Hospital,
Beijing, China
The Afﬁliated Hospital of the
Chinese Academy of Military
Medical Sciences, Beijing, China
Multiple locations in the USA

Not stated
Not stated
Escalated dosing; patients proceed to allo-SCT or alternative
therapy as clinically applicable
Not stated
Not stated

Escalated dosing; patients must
have a stem cell donor available
for potential allo-SCT
Escalated dosing

Not stated
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The First Afﬁliated Hospital of
Soochow University, Suzhou,
China
920th Hospital of Joint Logistics
Support Force of People's Liberation Army of China, Kunming,
Yunnan, China

Not stated
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CAR T-cell antigen target

(continued on next page)

NCT05023707 (Recruiting)

NCT04692948 (Recruiting)

Anti-FLT3

Anti-CD276

Information abstracted from www.clinicaltrials.gov using search terms “acute myeloid leukemia” and “CART” on 2/10/2022. R/R AML: relapsed/refractory acute myeloid leukemia;
BPDCN: blastic plasmacytoid dendritic cell neoplasm; allo-SCT: allogeneic hematopoietic-cell transplantation; EGFRt: truncated epidermal growth factor receptor; mAb: monoclonal
antibody; TCR: T-cell receptor; KO: knockout; GVHD: graft-versus-host-disease; TM: target module.

Not stated

NCT03896854 (Unknown)
Anti-CD19

R/R AML (18e70)

NCT04351022 (Recruiting)

R/R AML (16e65)

Trial number (status)

Anti-CD38

R/R AML (6e65)

Not stated

Escalated dosing

The First Afﬁliated Hospital of
Soochow University, Suzhou,
China
The First Afﬁliated Hospital of
Soochow University, Suzhou,
China
The First Afﬁliated Hospital of
Soochow University, Suzhou,
China
Anhui Provincial Hospital, Hefei,
Anhui, China
R/R AML (6e65)

Escalated dosing

Strategies to mitigate toxicity
Location
Disease subtype (age)
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macrophage progenitors [13]. CLL1-speciﬁc CAR in
combination with 4-1BB and CD28 signaling domains have been developed with strong antileukemic activity in a patient-derived xenograft
model of AML. Although CLL1þ myeloid progenitor cells and mature myeloid cells were eliminated
by CLL-1 CAR T-cells, normal HSPCs were spared,
allowing full myeloid recovery once CAR T activity
diminishes [14]. An autologous, gene-edited CAR
T-cell therapy that targets CLL-1 recently began
accruing R/R de novo or secondary AML patients at
multiple locations across the United States (clinicaltrials.gov identiﬁer: NCT04789408).
2.4. CD38
CD38 is another candidate antigen target as it is
expressed on most AML and multiple myeloma cells,
but not on normal HSPCs. A clinical trial using antiCD38 CAR T-cells in six AML patients who relapsed
after HCT was recently published (clinicaltrials.gov
identiﬁer: NCT04351022), where four patients achieved
a CR or CR with incomplete count recovery (CRi) and
full donor chimerism at four weeks after initial infusion. Remission lasted for a median of 6.4 (range
3.9e8.7) months, with median OS of 7.9 months for
this small cohort. One patient relapsed 3.9 months
after the ﬁrst anti-CD38 CAR T-cell infusion but achieved remission after repeated CAR T-cell treatment.
All patients experienced clinically manageable side
effects, with grade I-II CRS in most of the patients [15].

3. Novel approaches of CAR T-cell therapy in
AML
A number of other immunotherapeutic strategies
have been developed in AML including targeting
natural killer group 2D (NKG2D) ligands, compound CARs targeting dual antigen targets, rapidly
switchable CARs, recombinant bispeciﬁc CARs, and
utilizing genetically modiﬁed allografts followed by
CAR T-cell therapy.
3.1. NKG2D-CAR T-cell therapy
NKG2D ligands represent a promising target in
AML therapy as they are widely expressed in a wide
range of malignancies but absent or poorly
expressed on healthy cells. Researchers at the DanaFarber Cancer Institute conducted a phase I study to
evaluate the safety and tolerability of NKG2D-CAR
in patients with AML and other HM [16]. Seven
patients with R/R AML were recruited. There were
no objective tumor responses observed at low cell
dose with limited persistence of the CART
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population; however, there was an improvement in
hematologic parameters in one of two subjects at
higher dose levels. Additionally, the NKG2D-CAR
killing activity can be further enhanced via pharmacologic histone deacetylase (HDAC) inhibition
without affecting healthy cells [17]. This study
showed that NKG2D-CAR T-cell therapy combined
with HDAC-inhibitors represents a potential
approach to achieve anti-leukemic efﬁcacy in AML.

impact on CD13þ healthy normal cells. This enables
targeting of previously unrecognized surface antigens, which expands the ability to generate functional CARs in AML and other cancers [21]. This
approach is yet to be tested in clinical trials but
represents a highly attractive approach to harness
the immunotherapeutic power of T-cell therapy
while sparing the toxicities to normal HSPCs and
myeloid progenitors.

3.2. Compound CARs targeting dual antigen targets

3.5. Genetic inactivation of CD33 in HSPCs

A dual anti-CLL CAR linked to an anti-CD33 CAR
on the surface of a T-cell was developed and tested
in multiple AML cell lines with potent anti-leukemic
activity. This compound was tested in a ﬁrst-inhuman phase I dose escalation study in R/R AML
patients [18]. One patient achieved MRD-negative
CR on day 19 post CAR T-cell infusion with total
myeloid ablation in the bone marrow and subsequently underwent non-myeloablative HCT.
Results for other patients enrolled in this clinical
trial have not been reported.

Since targeting tumor-speciﬁc antigens is a major
hurdle to the development of CAR T-cell therapy
for AML, it may be possible to avoid destruction of
normal hematopoiesis by deleting certain antigens
from the normal HSPCs and enabling the CAR
T-cells to speciﬁcally target leukemic cells. Indeed,
one study showed that autologous CD33 knockout
(KO) bone marrow transplantation in animal
models was resistant to CD33þ CAR T-cells and
enabled anti-tumor activity while sparing the
normal cells [22]. Additionally, CD33-deﬁcient
myeloid cells were fully functional, suggesting
CD33 may not be essential for normal cellular
function and development. However, occult functional deﬁcits in CD33 KO myeloid cells cannot be
excluded, thus the clinical implications of translating this approach to humans are not yet clear.

3.3. Universal, rapidly switchable CAR T-cell
therapy
A novel rapidly switchable 2-component, nextgeneration CAR T-cell product using a universal
CAR T-cell in combination with a recombinant
antibody derivative called targeting module
directed against CD123 (TM123), was developed and
used to treat three R/R AML patients in a phase 1
trial (clinicaltrials.gov identiﬁer: NCT04230265) with
encouraging early results [19]. Two patients achieved a CRi and one patient had partial remission
(PR) as the best response. The half-life of TM123 is
no more than 30 minutes, thereby eliminating potential toxicity associated with persistence of CAR
T-cells and obviating the need for subsequent HCT,
but does require continuous intravenous infusion
for 24 days and repeated administration. There were
no dose-limiting toxicities and the adverse events
were generally mild.

4. Conclusions
Results from ongoing trials in CAR T-cell therapy
are eagerly awaited and will be crucial for understanding the role of this treatment option in the
management of AML patients. Continued progress
in identifying novel immunotherapeutic targets as
well as gene-modifying approaches appears to be a
promising strategy in preclinical models, although
its extensibility to humans remains limited. Safe and
tolerable CAR T-cells without signiﬁcant toxicity
such as those of myeloablation are urgently needed.
Together with established HCT, CAR T-cell therapy
has the potential to change therapeutic outcomes of
patients with AML.

3.4. Recombinant bispeciﬁc and split CAR
Researchers at the University of Pennsylvania
developed a system to identify tumor-speciﬁc antibodies to preferentially bind speciﬁc target antigens
that are highly expressed in AML cells,
thereby eliminating leukemic cells in preclinical
models [20]. A bispeciﬁc CAR targeting both CD13
and TIM3 was developed to effectively eradiate
CD13 þ TIM3þ leukemic cells, while reducing the
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